Ignite Creation Date:
2024-05-06 @ 12:37 AM
Last Modification Date:
2024-10-26 @ 10:52 AM
Study NCT ID:
NCT01614171
Status:
WITHDRAWN
Last Update Posted:
2022-04-08
First Post:
2012-06-05
Brief Title:
Growth Hormone for Osteoporosis Pseudoglioma Syndrome
Sponsor:
University of Maryland Baltimore
Organization:
University of Maryland Baltimore
Study Overview
Official Title:
Trial of Growth Hormone for Osteoporosis Pseudoglioma Syndrome
Status:
WITHDRAWN
Status Verified Date:
2017-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
it was never started because it was never funded
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
GHOPPG
Brief Summary:
Osteoporosis pseudoglioma OPPG syndrome is a rare autosomal recessive condition of childhood osteoporosis and congenital blindness for which new treatments are needed We have found that body fat is increased in OPPG and muscle mass is reduced We hypothesize that growth hormone therapy will improve muscle mass and bone strength in OPPG
Detailed Description:
Osteoporosis pseudoglioma OPPG syndrome is a rare autosomal recessive condition of childhood osteoporosis and congenital blindness for which new treatments are needed We have found that body fat is increased in OPPG and muscle mass is reduced We hypothesize that growth hormone therapy will improve muscle mass and bone strength in OPPG
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None